VSIR and non-small cell lung carcinoma: In contrast, several findings have shown that high levels of VISTA contribute to a favorable immune microenvironment and better overall survival for non-small-cell lung cancer (NSCLC), breast cancer, hepatocellular carcinoma, esophageal adenocarcinoma (EAC), and serous ovarian cancer (27–31).